Диссертация (1140119), страница 24
Текст из файла (страница 24)
Antidepressants in’depressed’ schizophrenic inpatients. A controlled trial // Arch. Gen. Psychiatry. - 1989.- Vol.46. - P.922–928.128124. Lee KU, Jeon YW, Lee HK, Jun TY. Efficacy and safety of quetiapine fordepressive symptoms in patients with schizophrenia. Hum Psychopharmacol 2009; 24:447-452.125. Liddle P. F. et al. Depression and the experience of psychological deficits inschizophrenia //Acta Psychiatrica Scandinavica.
– 1993. – Т. 88. – №. 4. – С. 243-247.126. Lindenmayer J., Grochowski S., Kay S.R. Schizophrenic patients withdepression: psychopathological profiles and the relationship with negative symptoms //Compr. Psychiatry. 1991. - Vol.32. - P.528–533.127. Lyons M.J. Epidemiology of personality disorders. // In: Textbook inpsychiatric epidemiology.
New York. 1995. – P.407-436.128. Maier W., Lichtermann, D., Klinger T. et al Prevalences of personalitydisorder (DSM^III^R) in the community. // Journal of Personality Disorders. 1992. –Vol.6. – P.187-196.129. Maneeton N., Maneeton B., Srisurapanont M., Martin S.D. Quetiapinemonotherapy in acute phase for major depressive disorder: a metaanalysis of randomized,placebo-controlled trials // BMC Psychiatry. 2012.
- Vol.12. - P.160.130. Marder SR, Davis JM, Chouinard G (1997) The effects of risperidone on thefive dimensions of schizophrenia derived by factor analysis: combined results of theNorth American trials. // J Clin Psychiatry. – 1997. – Vol.58. – P.538–546.131. Markovitz PJ, Calabrese JR, Schulz SC, Meltzer HY. Fluoxetine in thetreatment of borderline and schizotypal personality disorders.
// Am J Psychiatry.1991. –Vol.148. – P.1064-1067.132. Martin R. L. et al. Frequency and differential diagnosis of depressivesyndromes in schizophrenia //The Journal of clinical psychiatry. – 1985.133. Mauri MC, Moliterno D, Rossattini M, Colasanti A. Depression inschizophrenia: Comparison of first- and second-generation antipsychotic drugs.Schizophrenia Research 2008. – Vol.99 1–3).
– P.7–12.129134. McClure MM, Harvey PD, Bowie CR, Iacoviello B, Siever LJ. Functionaloutcomes, functional capacity, and cognitive impairment in schizotypal personalitydisorder. Schizophr Res. 2013. - Vol.144. – P.146–150.135. McGurk SR, Mueser KT, Mischel R, et al.
Vocational functioning inschizotypal and paranoid personality disorders. Psychiatry Res. 2013. – Vol.210. –P.498–504.136. Meehl PE. Schizotaxia, schizotypy, schizophrenia. // Am Psychol. 1962. –Vol.17(12). – P.827-38.137. Micallef J, Fakra E, Blin O. Use of antidepressant drugs in schizophrenicpatients with depression. // Encephale. 2006. – Vol.32(1). – P.263-269.138. Mitropoulou V, Harvey P, Maldari L, Moriarty P, New A, Silverman J,Siever L. Neuropsychological performance in schizotypal personality disorder: evidenceregarding diagnostic specificity. // Biol Psychiatry. 2002.
Vol.52(12)/ - P.1175–1182.139. Möller H.J. Occurrence and treatment of depressive comorbidity inschizophrenic psychoses: conceptual and treatment issues. // World J Biol Psychiatry.2005. – Vol.6(4). - 247-263.140. Möller HJ. Definition, psychopharmacological basis and clinical evaluationof novel/atypical neuroleptics: methodological issues and clinical consequences. // WorldJ Biol Psychiatry.
2000. – Vol.1. – P.75–91.141. Möller HJ. Antidepressive effects of traditional and second generationantipsychotics: a review of the clinical data. // Eur Arch Psychiatry Clin Neurosci. 2005.- Vol.255. – P.83–93.142. Möller HJ. Antipsychotic and antidepressive effects of second generationantipsychotics: two different pharmacological mechanisms? // Eur Arch Psychiatry ClinNeurosci. 2005 – Vol.255(3). – P.190-201.143. Möller HJ, von Zerssen D. Depression in schizophrenia. In: Burrows GD,Norman TR, Rubinstein G, editors. Handbook of studies on schizophrenia. Part 1.Amsterdam: Elsevier Science Publishers; 1986.
P. 183-91.130144. Mulholland C., Cooper S. The symptom of depression in schizophrenia andits management // Adv. Psychiatr. Treatment. 2000. - Vol.6. - P.169–177.145. Olie JP, Costa e Silva, Macher JP. Neuroplastisity. A new approach to thepathophysiology of depression. London: Science Press, 2004.146. Park S., McTigue K., Working memory and the syndromes of schizotypalpersonality. // Schizophr. Res. 1997. – Vol.26(2-3). – P.213– 220.147.
Pepper C.M., Klein D.N., Anderson R.L., Riso L.P., Guimette P.C., LizardiH. DSM-III-R axis II comorbidity in dysthymia and major depression. // Am. J.Psychiatry. 1995. – Vol.152. – P.239- 247.148. Peselow E.D., Sanfilipo M.P., Fieve R.R., Gulbenkian, G. Personality traitsduring depression and after clinical recovery. // Br.
J. Psychiatry. 1994. – Vol.164. –P.349-354.149. Peuskens J, Van Baelen B, De Smedt C, Lemmens P. Effects of risperidoneon affective symptoms in patients with schizophrenia. Int Clin Psychopharmacol. 2000. Vol.15. – P.343–349150. Peuskens J, Möller HJ, Puech A. Amisulpride improves depressivesymptoms in acute exacerbations of schizophrenia: comparison with haloperidol andrisperidone.
// Eur Neuropsychopharmacol. 2002. Vol.12(4). P.305-310.151. Pfohl B., Stangl D., Zimmerman M. The implications of DSM-IIIpersonality disorders for patients with major depression. // J. Affect. Disord. 1984. –Vol.7. – P.309-318.152. Pilkonis P., Frank E. Personality pathology in recurrent depression: nature,prevalence, and relationship to treatment response // Am. J. Psychiatry.
1988. Vol.145(7). - P.435–441.153. Plasky P. Antidepressants usage in schizophrenia. // Schizophr Bull 1991. –Vol.17(4). – P.649–657.154. Pulay AJ, Stinson FS, Dawson DA, et al. Prevalence, correlates, disability,and comorbidity of DSM-IV schizotypal personality disorder: results from the wave 2131national epidemiologic survey on alcohol and related conditions. // Prim Care CompanionJ Clin Psychiatry. 2009.
– Vol.11. – P.53–67.155. Raine A. Schizotypal personality: neurodevelopmental and psychosocialtrajectories. // Annu Rev Clin Psychol. 2006. – Vol.2. – P.291-326.156. Riedel M, Mayr A, Seemuller F et al. Depressive symptoms and theirassociation with acute treatment outcome in first-episode schizophrenia patients:comparing treatment with risperidone and haloperidol. // World J Biol Psychiatry. 2012.– Vol.13.
– P.30–38.157. Rosell DR, Futterman SE, McMaster A, Siever LJ. Schizotypal personalitydisorder: a current review. // Curr Psychiatry Rep. 2014. – Vol.16(7). – P.452.158. Rybakowski JK, Vansteelandt K, Szafranski T et al. Treatment of depressionin first episode of schizophrenia: Results from EUFEST. // Eur Neuropsychopharmacol.2012. – Vol.22 (12). – P.875–882.159. Samuels et al Samuels, J., Eaton,W.W., Bienvenu,O.
J., et al Prevalence andcorrelates of personality disorders in a community sample. // British Journal ofPsychiatry. 2002. Vol.180. – P.536-542.160. Samuel G. Siris, M.D. Depression in Schizophrenia: Perspective in the Eraof “Atypical” Antipsychotic Agents. // (Am J Psychiatry. 2000.
Vol.157. – P.1379–1389.161. Sands J.R., Harrow M. Depression during the longitudinal course ofschizophrenia // Schizophr. Bull. 1999. - Vol.25. - P.157–171.162. Schennach-Wolff R., Obermeier M., Seemuller F. et al. Evaluatingdepressive symptoms and their impact on outcome in schizophrenia applying the CalgaryDepression Scale. // Acta Psychiatr Scand. 2011. – Vol.123.
– P.228-238.163. Shanfield S., Tucker G.J., Harrow M., Detre T. The schizophrenic patientand depressive symptomatology. — J. Nerv. Ment. Dis. 1970; 151: 203-210.164. Siever L.J., Davis K.L. The pathophysiology of schizophrenia disorders:perspective from the spectrum. The American Journal of Psychiatry. 2004. – Vol.161.
–P.398–413.132165. Siever L.J., Koenigsberg H.W., Harvey P. et al.Cognitive and brain functionin schizotypal personality disorder. // Schizophrenia Res. –2002. – № 54. – P. 157–167.166. Siever L.J., Silverman J.M., Horvath T.B., et al. Increased morbid risk forschizophrenia-related disorders in relatives of schizotypal personality disordered patients.// Arch. Gen.
Psychiatry. 1990. – Vol.47. P.634–640.167. Siever L.J., Keefe R., Bernstein D.P., et al. Eye tracking impairment inclinically identified patients with schizotypal personality disorder. // Am. J. Psychiatry.1990. – Vol.147. – P.740–745.168. Siever LJ, Davis KL. The pathophysiology of schizophrenia disorders:perspectives from the spectrum. // Am J Psychiatry. 1993. – Vol.161(3).
– P.398–413.169. Simon A.E., Ferrero F.P., Merio M.C.G. Prodromes of first-episodepsychosis: how can we challenge nonspecificity // Comprehensive Psychiatry - 2001. Vol.42. - № 5. - Рр.382-392170. Siris S.G., Addington D., Azorin J.M. et al. Depression in schizophrenia:recognition and management in the USA. // Schizophr Res. 2001. Vol.47. – P.185-197.171.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
